Daewoong Pharmaceutical
069620 · KOSPI · South Korea
Public Market Listing
069620KOSPI
Live quotes, historical charts, and market capitalization for Daewoong Pharmaceutical are available on Yahoo Finance.
View quote & market cap on Yahoo Finance ↗External market data link · No third-party exchange redistribution
Assets
(7 total)
7Total Assets
0Approved
4Phase 3 / Filed
3Phase 1–2 / Early
6Diseases
Quick filter:
| Target & Modality | |||
|---|---|---|---|
| Phase 3 | Undisclosed / early pipelineSmall molecule | HypertensionAtherosclerotic Cardiovascular Disease | |
Enavogliflozin(Envlo) | Phase 3 | SGLT2Small molecule | Type 2 DiabetesChronic Kidney Disease |
Gemigliptin(Zemiglo) | Phase 3 | DPP-4Small molecule | Type 2 Diabetes |
| Phase 3 | Angiotensin II receptor / HMG-CoA reductaseSmall molecule | Hypertension | |
| Phase 1 | Nurr1 (NR4A2, nuclear orphan receptor)Small molecule | Parkinson's Disease | |
| Phase 1 | GLP-1 receptorPeptide | Obesity | |
OLOMAXNo recent activity | Preclinical / Unstaged | Angiotensin II receptor / Calcium channel / HMG-CoA reductaseSmall molecule | HypertensionAtherosclerotic Cardiovascular Disease |
Upcoming events
(1 total)
Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.
2027 (1)
November 2027 (1)
Est. primary completion 2027-11 · NCT07619833 · CT.gov ↗